Stivarga regorafenib regulatory update

Germany's Federal Joint Committee (G-BA) issued a final benefit assessment that found Stivarga regorafenib from Bayer has "marginal" additional benefit vs. best supportive care (BSC) to treat metastatic colorectal cancer (mCRC). The recommendation is in line with a January preliminary assessments from Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) (see BioCentury, Jan. 6). Bayer will now negotiate a price for Stivarga with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband). ...